In focus
Latest feed
AbbVie Takes the Leap: Why the $2.5 B Buy‑out of Apogee Therapeutics Could Redefine Immunology
The Next Frontier: How Pharma is Redefining GLP-1 Success Beyond the Pill
Johnson & Johnson's Bold Bet: Steering Clear of GLP-1 Hype to Double Down on Oncology
The Future of Immunity: Eli Lilly's Bold Strategic Play in Vaccine Development
